FATE THERAPEUTICS INC

Develops off-the-shelf iPSC cell therapies for cancer and autoimmune diseases.

FATE | NDAQ

Overview

Corporate Details

ISIN(s):: US31189P1021
LEI:
Country:: United States of America
Address:: 12278 SCRIPPS SUMMIT DRIVE, 92131 SAN DIEGO
Website:: https://fatetherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing first-in-class cellular immunotherapies for cancer and autoimmune diseases. The company utilizes its proprietary induced pluripotent stem cell (iPSC) platform to advance a pipeline of universal, "off-the-shelf" cell product candidates. These multiplexed-engineered therapies are designed to overcome key manufacturing and commercial limitations of conventional cell therapies. By incorporating novel synthetic controls of cell function, Fate's product candidates are intended to deliver multiple therapeutic mechanisms, aiming to make life-changing cell therapies routine and accessible for patients with life-threatening diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all FATE THERAPEUTICS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for FATE THERAPEUTICS INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for FATE THERAPEUTICS INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Entero Therapeutics, Inc. Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.	United States of America	ENTO
Entrada Therapeutics, Inc. Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.	United States of America	TRDA
ENZYCHEM LIFESCIENCES CORPORATION Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.	South Korea	183490
Enzymatica AB Develops medical devices with patented enzyme technology to treat upper respiratory infections.	Sweden	ENZY
Epi Biotech Co., Ltd. Developing alopecia therapies, skin regeneration products, and preclinical CRO services.	South Korea	446440
EQL Pharma AB Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.	Sweden	EQL
Equillium, Inc. Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.	United States of America	EQ
Erasca, Inc. Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.	United States of America	ERAS
Ernexa Therapeutics Inc. Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.	United States of America	ERNA
ERYTECH Pharma S.A. Developing phage therapies to combat antibiotic-resistant bacterial infections.	France	ERYP